错配修复状态影响子宫内膜癌保留生育功能治疗的反应
本研究评估ProMisE分子分型在57例子宫内膜癌患者保留生育功能治疗中的预后意义。错配修复缺陷患者激素治疗后最佳总体缓解率和6个月完全缓解率显著低于野生型p53患者,错配修复状态可能作为预测激素治疗获益的生物标志物。
要点
- 错配修复缺陷患者激素治疗最佳总体缓解率显著低于野生型p53患者
- 错配修复缺陷患者6个月完全缓解率显著低于野生型p53患者
- ProMisE分子分型有助于早期风险分层和指导保留生育功能治疗
核心结论
- ProMisE分子分型在子宫内膜癌保留生育功能治疗中具有预后意义
- 错配修复状态可作为预测激素治疗获益的生物标志物
研究设计与样本
- 回顾性分析57例激素治疗前子宫内膜活检标本
- 按ProMisE分子分型分为错配修复缺陷、DNA聚合酶ε突变、野生型p53和异常p53四类
- 主要终点为激素治疗后缓解率
主要发现
- 9例(15.8%)为错配修复缺陷,2例(3.5%)为DNA聚合酶ε突变,45例(78.9%)为野生型p53,1例(1.8%)为异常p53
- 总体激素治疗后完全缓解率为75.4%
- 错配修复缺陷患者中4例因治疗失败行全子宫切除术,3例术后诊断升级
临床怎么用
- 对保留生育功能的子宫内膜癌患者可考虑检测错配修复状态以预测激素治疗反应
- 错配修复缺陷患者激素治疗反应率较低,需早期识别并考虑更积极的干预
局限性
- 样本量较小(57例),结果需在更大规模研究中验证
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients younger than 40 years usually present with early-stage endometrial cancer with favorable prognosis. However, such patients are usually in their childbearing age and may desire fertility-sparing options. The identification of biomarkers may improve the clinical outcomes in these patients and aid in fertility-sparing management; however, there has been no reports on biomarker analysis so far. OBJECTIVE: This study aimed to evaluate the prognostic significance of Proactive Molecular Risk Classifier for Endometrial Cancer in the fertility-sparing management of endometrial cancer. STUDY DESIGN: A total of 57 endometrial biopsy specimens obtained before hormone therapy were evaluated, and patients were classified according to the Proactive Molecular Risk Classifier for Endometrial Cancer molecular subtypes (mismatch repair deficiency, DNA polymerase epsilon mutation, wild-type p53, and abnormal p53). The primary endpoint was the response rate after hormone therapy. The secondary endpoint was the recurrence rate after the complete response, hysterectomy rate owing to treatment failure, and upstaged diagnosis rate after hysterectomy. RESULTS: Of 57 patients, 9 (15.8%) had mismatch repair deficiency, 2 (3.5%) had DNA polymerase epsilon mutation, 45 (78.9%) had wild-type p53, and 1 (1.8%) had abnormal p53. Overall, the complete response rate was 75.4% after hormone therapy. Patients with mismatch repair deficiency had a significantly lower complete response or partial response rate than those with wild-type p53 in terms of the best overall response (44.4% [95% confidence interval, 4.0-85.0] vs 82.2% [95% confidence interval, 71.0-94.0]; P=.018) and complete response rate at 6 months (11.1% [95% confidence interval, 0.2-37.0] vs 53.3% [95% confidence interval, 38.0-68.0]; P=.010). Among patients with mismatch repair deficiency, 4 underwent immediate hysterectomy because of treatment failure and 3 presented upstaged diagnosis after hysterectomy. CONCLUSION: The Proactive Molecular Risk Classifier for Endometrial Cancer molecular classification has prognostic significance in the fertility-sparing management of endometrial cancer, thereby enabling early stratification and risk assignment to direct care. Mismatch repair status could be used as a predictive biomarker for selecting patients who could benefit from hormone therapy. These findings need to be validated in larger studies.
引用
- Chung YS, Woo HY, Lee JY, et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. Am J Obstet Gynecol. 2020. PMID: 33039397. doi:10.1016/j.ajog.2020.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。